These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27903969)

  • 1. Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer.
    Hu Z; Xu J; Cheng J; McMichael E; Yu L; Carson WE
    Oncotarget; 2017 Jan; 8(1):1481-1494. PubMed ID: 27903969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
    Hu Z; Shen R; Campbell A; McMichael E; Yu L; Ramaswamy B; London CA; Xu T; Carson WE
    Cancer Immunol Res; 2018 Jun; 6(6):671-684. PubMed ID: 29622581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.
    Hu Z; Rao B; Chen S; Duanmu J
    BMC Cancer; 2010 May; 10():235. PubMed ID: 20504328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy.
    Hu Z; Cheng J; Xu J; Ruf W; Lockwood CJ
    Angiogenesis; 2017 Feb; 20(1):85-96. PubMed ID: 27807692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy.
    Duanmu J; Cheng J; Xu J; Booth CJ; Hu Z
    Br J Cancer; 2011 Apr; 104(9):1401-9. PubMed ID: 21427724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment of human lung cancer by targeting tissue factor with a factor VII-targeted photodynamic therapy.
    Cheng J; Xu J; Duanmu J; Zhou H; Booth CJ; Hu Z
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1069-81. PubMed ID: 21933104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
    Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells.
    Cheng JY; Hung JT; Lin J; Lo FY; Huang JR; Chiou SP; Wang YH; Lin RJ; Wu JC; Yu J; Yu AL
    Front Immunol; 2021; 12():791551. PubMed ID: 35046949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
    Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
    Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel model for evaluating therapies targeting human tumor vasculature and human cancer stem-like cells.
    Burgos-Ojeda D; McLean K; Bai S; Pulaski H; Gong Y; Silva I; Skorecki K; Tzukerman M; Buckanovich RJ
    Cancer Res; 2013 Jun; 73(12):3555-65. PubMed ID: 23576551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
    Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
    Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
    Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
    Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
    Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
    Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
    Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
    Casagrande F; Cocco E; Bellone S; Richter CE; Bellone M; Todeschini P; Siegel E; Varughese J; Arin-Silasi D; Azodi M; Rutherford TJ; Pecorelli S; Schwartz PE; Santin AD
    Cancer; 2011 Dec; 117(24):5519-28. PubMed ID: 21692061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.
    Damelin M; Bankovich A; Park A; Aguilar J; Anderson W; Santaguida M; Aujay M; Fong S; Khandke K; Pulito V; Ernstoff E; Escarpe P; Bernstein J; Pysz M; Zhong W; Upeslacis E; Lucas J; Lucas J; Nichols T; Loving K; Foord O; Hampl J; Stull R; Barletta F; Falahatpisheh H; Sapra P; Gerber HP; Dylla SJ
    Clin Cancer Res; 2015 Sep; 21(18):4165-73. PubMed ID: 26015513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer.
    Hu Z; Rao B; Chen S; Duanmu J
    Breast Cancer Res Treat; 2011 Apr; 126(3):589-600. PubMed ID: 20514515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.
    Damelin M; Bankovich A; Bernstein J; Lucas J; Chen L; Williams S; Park A; Aguilar J; Ernstoff E; Charati M; Dushin R; Aujay M; Lee C; Ramoth H; Milton M; Hampl J; Lazetic S; Pulito V; Rosfjord E; Sun Y; King L; Barletta F; Betts A; Guffroy M; Falahatpisheh H; O'Donnell CJ; Stull R; Pysz M; Escarpe P; Liu D; Foord O; Gerber HP; Sapra P; Dylla SJ
    Sci Transl Med; 2017 Jan; 9(372):. PubMed ID: 28077676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.